摘要
目的研究匹多莫德治疗传染性单核细胞增多症(IM)的临床疗效及对T淋巴细胞亚群的影响。方法采用流式细胞术检测了53例IM患儿和20名健康儿童外周血淋巴细胞亚群。将53例IM患儿随机分为两组,对照组25例和干预治疗组28例,两组均给予常规处理,IM干预组在常规治疗的基础上加用匹多莫德,予以比较。结果1与健康组比较,IM患儿CD3+、CD8+淋巴细胞上升明显(P<0.01),CD4+淋巴细胞和CD4+/CD8+比值降低明显(P<0.01);2匹多莫德治疗两周后,CD3+、CD8+淋巴细胞比例降低,CD4+淋巴细胞比例及CD4+/CD8+比值明显升高,差异有显著性(P<0.01);3两组IM患儿的热程、咽峡炎缓解时间、淋巴结肿大消退时间及住院日均有显著差异(P<0.05)。结论匹多莫德能改善IM患儿的细胞免疫功能,且有良好临床疗效。
Objective To study the clinical efficacy of pidotimod in the treatment of infectious mononucleosis（IM） and its impact upon T-lymphocyte subgroups. Methods Flow cytometry was adopted to detect peripheral blood lymphocyte subgroups in 53 IM children patients and 20 healthy children. The 53 IM children patients were randomly divided into control group（n=25） and intervention therapy group（n=28）. Conventional therapy were performed in both groups, while intervention group received pidotimod-combined therapy additionally. Comparison was then carried out. Results（1）When compared with healthy children,the levels of CD3＋and CD8＋lymphocyte were significantly elevated（P〈0.01） in the IM children,while the level of CD4＋lymphocyte and the CD4＋/CD8＋ratio decreased significantly（P〈0.01）;（2）After pidotimod treatment for 2 weeks, ratios of both CD3＋and CD8＋lymphocyte were decreased, while the level of CD4＋lymphocytes and CD4＋/CD8＋ratio increased obviously. The differences were statistically significant（P〈0.01）;（3）The differences of the fever course, angina remission period,lymph node enlargement regression period and hospitalization days between two groups were all statistically significant（P〈0.05）. Conclusion Pidotimod can improve the cellular immune function in IM children as well as holds a favorable clinical effects.
出处
《中国现代医生》
2015年第7期4-7,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2012KYB193)
